Search

A recent article in the Journal of Infectious Diseases explores the potential use of loratadine, an over-the-counter antihistamine, as a treatment for Clostridioides difficile infection (CDI). The authors conducted preclinical studies using murine and hamster models, as well as human cell lines and colonic explants, to demonstrate the anti-inflammatory effects of loratadine in CDI. The findings suggest that loratadine may attenuate toxin B-mediated colonic inflammation, independent of histamine receptors but dependent on SRC and NFкB. However, the authors note that the optimal dosage of loratadine for CDI treatment is unclear, and further research is needed to assess its safety and efficacy in humans. [Extracted from the article]

Competing Interests: Potential conflicts of interest. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ciaran Kelly has acted as a paid consultant to: Facile Therapeutics, Ferring Pharma, Finch, Fzata, Merck, Milkyway Life Sciences, Pfizer, Recursion, RVAC Medicines, Seres Therapeutics, Summit Therapeutics and has acted as a study investigator for: Milkyway Life Sciences and Merck.